BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart™ Technology to Enhance the Use of Insulin Pumps
Unique Side-Ported Catheter Designed to Offer Consistent Insulin Delivery and Fewer Flow Interruptions including Silent Occlusions
Infusion Set Developed in Collaboration with
BD collaborated with JDRF and
"We believe that our new infusion set with BD FlowSmart technology is a ground-breaking innovation in diabetes technology that redefines the role of infusion sets in pump therapy by reducing the incidence of silent occlusions," said
"JDRF is excited to see the potential of BD's new infusion set for people with type 1 diabetes," said
"Now more than ever before, we believe that philanthropy is uniquely positioned to partner with industry to help incentivize and catalyze the development of new therapies and treatments for people with type 1 diabetes," said
In a previously presented head-to-head clinical study with a leading infusion set, subjects using the infusion set with BD FlowSmart technology had significantly fewer flow interruptions and less time spent with interrupted flow.ii Three studies featuring the new infusion set with BD FlowSmart technology will be presented during the
The infusion set with BD FlowSmart technology received approval for sale in
Product availability is expected in fiscal year 2016. To register for more information, please visit www.bd.com/infusionset.
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, policy influence and a working plan to bring life-changing therapies from the lab to the community. As the largest charitable supporter of T1D research, JDRF has invested nearly
i Bolick, Natasha, et al. "Reduction of Silent Occlusion Occurrence During Continuous Subcutaneous Insulin Infusion." ATTD.
ii Gibney M, et al. Continuous Subcutaneous Insulin Infusion (CSII) sets – Reduced flow interruptions with a novel investigational catheter infusion set. Diab Tech Ther 2015 (Suppl 1);17:A-8
iii van Bon A, et al. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diab Tech Ther 2011;13(6):607-614
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bd-receives-fda-clearance-for-a-novel-infusion-set-with-bd-flowsmart-technology-to-enhance-the-use-of-insulin-pumps-300082370.html
Lindsay Roman, BD, 201.847.4312, email@example.com; or Christopher Rucas, JDRF, 212.479-7667, firstname.lastname@example.org; or Laura Fahey, The Helmsley Charitable Trust, 212.953.2814, email@example.com